



The *new standard*
in digital pathology
and precision surgery.

Optiscan Imaging Ltd.
(ASX:OIL)

Annual General Meeting
14 November 2025



Notice

This presentation has been prepared by Optiscan Imaging Limited (OIL or the Company) on 14 November 2025 and approved for market release by the Board of Optiscan.

The information in this presentation is of a general nature and does not purport to be complete. The presentation does not contain all of the information which a prospective investor may require in evaluating a possible investment in OIL or that would be required in a prospectus or product disclosure statement prepared in accordance with the requirements of the Corporations Act 2001 (Cth). No representation or warranty, express or implied, is made as to the fairness, accuracy, completeness or correctness of the information, opinions and conclusions contained in this presentation. Neither OIL, nor any of its officers, employees, officers, agents, consultants or advisers are under any obligation to update any information subsequent to the issue of this presentation.

Future Performance

This presentation contains certain forward-looking statements and unaudited information including regarding the Company's future growth plans, strategies, products, operating performance, milestones, guidance, opinions, estimates, targets, goals, forecasts, earnings and financial position (Forward Looking Statements). The Forward Looking Statements, in this presentation are based on assumptions and contingencies which are subject to change without notice. Actual results and achievements could be significantly different from those expressed in or implied by this presentation. The Forward Looking Statements involve subjective judgements and assumptions as to future events which may or may not be correct and should not be relied upon as an indication or guarantee of future performance. No representation, warranty or assurance (express or implied) is given or made in relation to the achievement of any Forward Looking Statement by any person (including OIL).

Subject to any continuing obligations under applicable law, OIL disclaims any obligation or undertaking to provide any updates or revisions to any Forward Looking Statement in this presentation to reflect any change in expectations in relation to any such Forward Looking Statement or any change in events, conditions or circumstances on which any such statement is based. Nothing in this presentation will create an implication that there has been no change in the affairs of OIL since the date of this presentation.

Past performance

The operating and historical financial information in this presentation are not an indication of OIL's views on its future performance or condition. Actual results could differ materially from those referred to in this presentation. Past performance of OIL is not and cannot be relied upon as an indicator of (and provides no guidance as to) future performance.

Not an offer or financial product advice

This presentation is not a prospectus, product disclosure statement or other offering document under Australian law (and will not be lodged with ASIC) or any other law. This presentation does not satisfy the disclosure requirements for a disclosure document required under the Corporations Act. This presentation is for information purposes only and is not an invitation or offer of securities for subscription, purchase or sale in any jurisdiction. This presentation does not constitute investment or financial product advice (nor tax, accounting or legal advice) or any recommendation to acquire securities and does not and will not form any part of any contract for acquisition of securities. Each recipient of this presentation should make its own enquiries and investigations regarding all information in this presentation (including, without limitation, the assumptions, uncertainties and contingencies which may affect the future operations of OIL and the impact that different future outcomes may have on OIL).

This presentation has been prepared without taking into account any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, prospective investors should consider the appropriateness of the information having regard to their own investment objectives, financial situation and needs and seek legal, accounting and taxation advice appropriate to their jurisdiction. An investment in OIL's shares is subject to known and unknown risks, some of which are beyond the control of OIL. OIL does not guarantee any particular rate of return or the performance of OIL.

Liability

Neither OIL nor any of its officers, employees, officers, agents, consultants or advisers owe any duty (whether in equity, in tort or otherwise) to any investor in connection with this presentation nor do they have any liability (including, without limitation, in negligence) for any loss or damage arising from or in connection with this presentation, except to the extent that such liability may not lawfully be excluded.

To the maximum extent permitted by law, you acknowledge and agree that by taking part in this presentation you will not bring or institute any legal proceedings in contract, in tort, for breach of statutory duty or otherwise against OIL or any of its officers, employees, officers, agents, consultants or advisers in respect of any information provided to it in or in connection with this presentation.

Chairman's Address



Mr Robert Cooke
Non-Executive Chairman

Optiscan Board: Experienced Leadership



Robert Cooke
Board Chair

- 40-year career in health industry
- Executive leadership roles in healthcare companies in Australia, Asia and UK



Camile Farah
CEO & MD

- 25 years' experience in healthcare leadership, medical research, medtech R&D
- Dual trained physician and pathologist with international reputation and network



Sean Gardiner
Non-Executive Director

- Managing Director of Clermont Capital, Singapore
- 20 years' experience in equity research, with senior roles at Morgan Stanley



Karen Borg
Non-Executive Director

- Medtech leader who has held senior executive roles in private and public sectors
- Formerly with Johnson & Johnson USA, currently with SomnoMed



Ron Song
Non-Executive Director

- Track record of developing highly profitable ventures with a network of global contacts
- Formerly managed BMW & Audi dealerships in APAC

Chairman's Address

Optiscan Imaging Limited (ASX: OIL) (the 'Company' or 'Optiscan') provides the following Chairman's address which will be made to the Annual General Meeting of shareholders on 14 November 2025.

Dear Fellow Shareholders,

During FY25, Optiscan marked a major step forward in its evolution, progressing from a development-focused organisation to one actively advancing clinical validation and commercial readiness across its technology portfolio.

Secure Financial Footing

As we reflect on the achievements of FY25, it is appropriate to call out the strong support received from you, our shareholders, during the capital raise event which the Company undertook in the first quarter of FY26. The successful raising of \$17.75 million occurred on the back of significant positive progress of this Company's stated objectives towards commercialisation of its outstanding technology. We thank all our shareholders for their participation, and in particular our major shareholder Peters Investments Ltd for their support and backing of the rights issue.


Clinical and Product Milestones

The Company achieved several significant milestones during the year, led by the introduction and transition of its three cornerstone devices - InForm™, InVue®, and InSpecta™ - into clinical and commercial progression.

InForm™, designed for point-of-care and laboratory applications, was unveiled and advanced into the clinical validation phase. The InVue® device was prepared for clinical studies in breast-conserving surgery, with the first study initiated at the Royal Melbourne Hospital and a further program progressing with the Mayo Clinic in the United States. The InSpecta™ veterinary device was also revealed, extending Optiscan's technology into the rapidly growing veterinary medicine sector.

Technological Progress and Platform Expansion

The Company also achieved a major milestone with its Telepathology Platform, reaching Minimum Viable Product (MVP) stage and enabling real-time remote visualisation of high-resolution digital pathology images. At the same time, Optiscan advanced development of its AI-based imaging capabilities for gastrointestinal and pathology applications, supported by clinical studies underway in Germany.



Chairman's Address

Operational Excellence and Manufacturing Performance

Optiscan's manufacturing and engineering performance remained strong, achieving 100% on-time fulfilment for the second consecutive year, with new probe and scanner designs validated and delivered for upcoming clinical programs.

The Company also strengthened its quality management systems, completing implementation of its Greenlight Guru eQMS platform and achieving positive ISO audit outcomes, which are key steps in supporting regulatory progress and readiness for future market entry.

Global Collaborations and R&D Leadership

Optiscan's global partnerships deepened during the year, with collaborative work continuing with Mayo Clinic, Monash University, and University Medical Center Mainz under the \$3 million CRC-P grant for next-generation imaging development.

Optiscan also announced an exclusive collaboration agreement with Long Grove Pharmaceuticals which will see both companies work together to develop new intended uses for Long Grove's intravenous fluorescein sodium contrast agent (AK-FLUOR®).

Commercial Progress

Commercially, Optiscan expanded its footprint across the US, Europe, and China, supported by conference engagement, new business development activity, and a growing network of clinical and research collaborators.

Looking Ahead

The Company is well positioned to build on these achievements in FY26, as it continues to advance regulatory validation, strengthen its commercial pipeline, and deliver on its vision to transform healthcare through real-time, high-resolution imaging.

I would like to thank our executive team and employees for their continued dedication and contribution during the year as Optiscan progresses toward global market readiness.

On behalf of the Board, I would also like to extend our thanks to shareholders for their ongoing support and confidence in Optiscan's strategy and direction.



Managing Director's Report



Dr. Camile Farah
CEO & Managing Director

Acknowledgement of Country



I begin today by acknowledging the Traditional Owners of the land on which we meet, the Wurundjeri and the Boon Wurrung people of the Kulin Nation, and pay my respects to their Elders past, present and emerging.

Pathology - the weakest link in modern medicine

- **Every field of medicine relies on pathology** — yet it remains analogue, slow, and reactive.
- **Surgeons operate partly blind**, without real-time tissue assessment.
- **Repeat procedures and delayed results** create more risk, overload hospitals, delay treatments and create uncertainty for patients.
- **Critical decisions can take days**, delaying treatment and outcomes in every specialty.
- **Healthcare systems absorb billions in wasted cost**, inefficiency, and lost productivity.
- Billions are spent on robotics and imaging, but **critical decisions are still made on analogue glass slides**.



From bottleneck to breakthrough

Imagine pathology that's **real-time, digital**, and **at the point of care**!

Imagine doctors diagnosing conditions **on the spot without biopsies** or delays!

Imagine surgeons treating cancers completely **first time, every time**!

Imagine pathologists **seeing cells live** during the operation, not days after it!


This isn't the future - this is now.

This is Optiscan Imaging!



One technology, many markets

- **Medical:** real-time surgery, digital pathology, robotic integration.
- **Veterinary:** oncology, minimally invasive procedures, point of care.
- **Telepathology and AI/ML:** remote consultation, digital workflows, decision support.
- **Life sciences:** live, longitudinal imaging, reduced biopsies, accelerated discovery.



The next era of medicine

Clinical Device Family Vision



+

Full Suite of Digital Health Assets



Live Streaming
Telepathology Software &
Remote Diagnostics



AI Based Software as a
Medical Device



Biopsy Channel Compatible
Devices



Integration with Robotics
Systems



Image-guided
Molecular Surgery

Horizontally and Vertically integrated product range with large addressable markets

Optiscan^o

FY25



FY25 – A year of convergence

FY25 marked a pivotal point in Optiscan's journey — the year our technology, partnerships, and clinical programs came together to advance from **development** to **validation**.

Why it matters

Every milestone achieved this year was part of a **deliberate strategy** to strengthen regulatory readiness and position the Company for commercial growth.

FY25 demonstrated platform maturity, organisational alignment, partnership strength and clinical advancement, with our company now positioned for strategic growth.

Key pillars of progress

- **Organisational readiness** - Building the structure, leadership, and capability to scale globally.
- **Technology development** - Advancing device, software, and quality systems to meet global standards.
- **Established partnerships** - Expanding collaborations that accelerate validation and broaden application.
- **Clinical validation** - Generating clinical data to support regulatory submissions and future market entry.

Building the bridge to submission

A Year of Strategic Progress

FY25 marked a pivotal year in Optiscan's transformation as the company moved from development to clinical validation and laying the operational, technical, and regulatory foundations required for future regulatory submissions.

Clinical Milestones

- Ethical and regulatory approvals achieved for multiple studies.
- Royal Melbourne Hospital breast cancer study commenced, generating critical data for clinical validation.
- GI study initiated in Germany with first prototype imaging underway.

Technology and Product Development

- Reveal of InForm™ for pathology and InSpecta™ for veterinary medicine, expanding Optiscan's validated device portfolio.
- Completion of Telepathology Platform MVP, enabling real-time image access and review, now available on InVue®, InForm™ and InVivage®.
- Continued next-generation flexible probe and scanner development to meet regulatory and clinical performance benchmarks.

Partnerships and Collaboration

- Deepened clinical and academic partnerships, including Mayo Clinic, Monash University, and University of Minnesota.
- New agreement with Long Grove Pharmaceuticals to support future fluorescence imaging applications.
- Recent agreement with Australian Clinical Labs to support the validation, testing and deployment of InForm™ in a real-world pathology environment.

Regulatory and Readiness

- Comprehensive documentation, testing, and certification progressed for InVue®, InForm™ and InVivage® in preparation for US-based clinical studies.
- Strengthened quality systems and internal processes to meet international regulatory standards.

Why It Matters

These achievements collectively move Optiscan from R&D to a regulatory-ready position with validated clinical data, mature technology, and global partnerships that support the path to premarket submissions and future market entry.



Significant milestones FY25

Key Achievements FY25		
Clinical	Optiscan Receives Ethical Clearance for Breast Cancer Study Ethical clearance received from the Royal Melbourne Hospital Human Research Ethics Committee to undertake an in vivo clinical study for assessment of cancer margins in patients presenting for surgical treatment of breast cancer.	July 2024
Technology	Major Milestone In Telepathology Platform Successfully completed the beta phase of its innovative cloud-connected telepathology platform, developed in partnership with Prolucid Technologies.	July 2024
Partnership	MOU signed with University of Minnesota Memorandum of Understanding (MOU) signed with the University of Minnesota College of Veterinary Medicine to work towards a collaborative research agreement to trial clinical applications and develop clinical data for Optiscan's InSpecta.	August 2024
Partnership	Agreement with Monash University signed to Progress GI Scope An agreement signed with Melbourne-based Monash University that will help advance Optiscan's project to develop the next-gen gastrointestinal (GI) flexible endomicroscope and Edge-AI-enabled technology.	November 2024
Partnership	Research Agreement signed with Minnesota Vet College Collaborative Research Agreement signed with the University of Minnesota College of Veterinary Medicine which will enable the development of clinical data for InSpecta with an initial focus on cancer research in companion animals.	November 2024
Finance	\$1.775 R&D Tax Refund Refund strengthens Optiscan's balance sheet and supports continued investment in product development and clinical programs.	January 2025
Clinical	GI Study in Germany initiated with First Prototype Completed the first prototype to collect images from the gastrointestinal (GI) tract, as well as the commencement of an important pre-clinical GI study with University Medical Centre of the Johannes Gutenberg University Mainz, Germany.	February 2025

Significant milestones FY25

Key Achievements FY25		
Product	InForm Imaging Device Revealed for Pathology Reveal of Optiscan's digital pathology device, expanding the Company's clinical portfolio.	February 2025
Corporate	Announce new CFO and Executive Appointments Strengthened leadership team with new finance and executive roles to support Optiscan's global growth and commercialisation strategy.	March 2025
Partnership	Robotic Surgery Collaboration with Mayo Clinic Progresses Optiscan, in combination with the Mayo Clinic, has advanced the development of its digital confocal laser endomicroscopic imaging system for use in robotic surgery.	May 2025
Technology	Completed cloud-based Telepathology Software MVP Successfully completed the prototype of Optiscan's cloud-based telepathology streaming software solution marking the project's completion of the MVP stage.	May 2025
Product	InSpecta Device Revealed for Veterinary Medicine Introduction of Optiscan's veterinary imaging device, purpose-built for real-time cellular visualisation in animal health applications.	June 2025
Partnership	Agreement Signed with Long Grove Pharmaceuticals An exclusive collaboration agreement to develop new intended uses for Long Grove's intravenous fluorescein sodium contrast agent (AK-FLOUR®).	June 2025
Clinical	Breast Cancer Study Initiated at Royal Melbourne Hospital First in-human breast cancer study initiated which will utilise Optiscan's innovative InVue® precision surgery and InForm™ digital pathology imaging devices.	June 2025

Advancing Digital Pathology Locally



ASX Announcement
10 November 2025 (Melbourne, Australia)
Optiscan Imaging Ltd (ASX:OIL)

Optiscan Partners with ACL to Advance Digital Pathology

Optiscan Announces Strategic Collaboration with Australian Clinical Labs (ASX: ACL) to Accelerate Digital Pathology Innovation and Deployment.

Highlights

- Optiscan has signed a Collaboration Agreement with Australian Clinical Labs (ACL) to support the deployment and testing of its InForm™ digital pathology platform.
- ACL will provide access to its extensive laboratory network, enabling Optiscan to validate the InForm™ device in real-world conditions and collect imaging data from a broad range of human tissues and pathologies.
- Optiscan will test the InForm™ digital pathology device within ACL's flagship anatomical pathology laboratory in Western Australia.
- The collaboration supports pathologist training, regulatory submissions, and accelerates the wider adoption of digital pathology solutions, enhancing both Optiscan's technology and ACL's digital capabilities.
- The collaboration represents a major milestone in transforming pathology by allowing end-to-end real-time digital analysis of samples at the point of contact with tissue.



Advancing Digital Pathology Globally



TUESDAY 11/18/25



Keynote Session

11:00 - 12:00

James (Jim) Rogers III, CEO of Mayo Clinic Digital Pathology, will open the session with an inside look at Mayo Clinic's approach to capturing digital pathology's transformative potential. Then, Camile Farah, Ph.D., CEO and managing director of Optiscan Imaging, Ltd., will deliver a keynote address to share his expert insights into the evolving landscape of digital pathology and its role in shaping the future of clinical and surgical decision-making.

[— View more](#)

Mayo Clinic's Approach to Advancing Digital Pathology

11:00 - 11:15



James (Jim) Rogers III
CEO, Mayo Clinic Digital Pathology

Keynote Address

11:15 - 11:45






Camile Farah, Ph.D., M.B.A., MAICD, FAIM, FLWA
CEO & Managing Director, Optiscan Imaging

Financials



Secure financial footing



3 new devices revealed over last 18 months

- InVue® for precision surgery, InForm™ for digital pathology and InSpecta™ for veterinary medicine provide commercial opportunities to multi-million-dollar markets.
- Investment in R&D over the past 2 years has diversified the clinical applications for our technology, and associated market opportunities.

Total Income up ~14% on FY24 to \$4m


- Non-dilutive funding has increased as a result of additional R&D activities and associated tax incentives for overall expenditure.
- \$1.77m cash received for R&D tax incentive, a significant increase from \$0.67m received in FY24.

\$17.75m raised to fund transformation

- Clinical studies, testing and certification of InVue®, InForm™ and InSpecta™ to achieve US FDA regulatory approvals.
- Completion of R&D for flexible and robotics devices.
- Commercial planning for market launch.

Key financial information

Shareholders



FY2025 Financial Information

Revenue	\$0.95m
EBITDA	(\$5.84m)
Total Assets	\$10.55m
Total Liabilities	\$2.84m

As of 30 Sep 2025

Cash	\$19.99m*
Capital raised	\$17.75m


**Unaudited*

Growth in Motion




From invention to commercialisation

- Optiscan is on a transformation journey; **from OEM to pure play digital solutions provider.**
- Optiscan now sits at a significant juncture; **crossing from product development to commercial adoption.**



Devices with impact

ViewnVivo®
(Life sciences)



InSpecta™
(Veterinary)



InVivage®
(Oral)



InVue®
(Surgery)




InForm™
(Pathology)



Clinical Testing & Regulatory Submissions Underway

Product pipeline



Current stage of progress

Commercialisation growth stages

2025

Market opportunity

- a) Pre-clinical research market: \$5.7B
- b) OEM producer for Carl Zeiss

Notes:

- Optiscan validated technology has been used in more than 150 publications
- Currently 2 products sold in market
- ViewnVivo sold directly to market and through distributor



2026

Market opportunity

Veterinary market: \$46.51B

Notes:

- Regulatory work underway with FDA submission planned for 2026, and market launch
- Lucrative veterinary market in the surgical and pathology space for InSpecta™ device



2027

Market opportunity

- a) Surgery-Open(Breast and Head & Neck): \$30B
- b) Pathology: \$35.1B

Notes:

- Regulatory work in progress with anticipated market launch planned for 2027
- Large US market opportunity with devices being validated by partner institutions, notably Mayo Clinic



2028+

Market opportunity

- a) Surgery-Robotics: \$3.92B
- b) Oral Imaging: \$1.9B
- c) GI: \$185B

Notes:

- Robotics market is rapidly expanding and will only continue to do so with advancement in tech.
- GI project will include the next-generation GI flexible endomicroscopes powered by AI technology.



Market Oppprtunities



Growth opportunities

>\$100B market opportunity

Veterinary

InSpecta™



Surgery

InVue®



Pathology

InForm™



Veterinary market

InSpecta™

ASPECT	PAST (PRE-2015)	PRESENT & FUTURE (2025+)
Care Model	Reactive, walk-in	Hybrid, proactive, digital-first
Technology Use	Minimal	AI, wearables, telehealth, 3D printing
Revenue Model	Fee-for-service	Subscription, wellness plans
Telemedicine	Rare	300% growth in 2020–2021
Client Engagement	In-person only	Digital platforms, apps, remote care
Practice Ownership	Solo practices	Corporate consolidation, M&A growth

Surgery market

InVue®

METRIC	TRADITIONAL - OPEN SURGERY	MODERN – MINIMALLY INVASIVE & ROBOTIC
Incision Size	Large	Small (laparoscopic) or micro (robotic)
Recovery Time	Longer (weeks)	Shorter (days to a week)
Hospital Stay	5–10 days	1–3 days (robotic often <2 days)
Complication Rate	Higher	Lower (especially infections and bleeding)
Decision-Making Efficiency	Surgeon-dependent	Enhanced by imaging, AI, and planning tools
Market Growth	Static (no specific growth data)	Rapid growth: devices market CAGR 6.7%-8.7% , robotics projected ~ \$16.8B by 2030

Pathology market

InForm™

METRIC	TRADITIONAL PATHOLOGY	DIGITAL PATHOLOGY
Turnaround Time	Slow due to manual handling	Up to 50% faster with digital & AI
Cost	Low upfront, high operational	High initial, long-term savings
Market Opportunity (US)	Mature market	USD \$1.5B (2024) → USD \$4.5B (2035)
Growth Rate	Flat or declining	CAGR 10.5%–16.9%
Adoption Rate	Widely used, limited scalability	60%+ labs use digital scanners; 47% use AI; 58% use telepathology
Efficiency & Accuracy	Manual, delays	40% workload↓, 34% speed↑ (faster diagnosis)

Gastrointestinal (GI) market

GI Flexible Device		
METRIC	TRADITIONAL GI PRACTICES	MODERN GI PRACTICES
Technology	Manual endoscopy, X-rays, barium studies	AI-assisted colonoscopy, capsule endoscopy, molecular imaging
Precision & Personalization	General treatment protocols, symptom-based diagnosis	Personalized medicine based on genetics, microbiome; AI predictions
Cost Efficiency	Initial Cost: Lower	Initial Cost: Higher (advanced tech, AI systems, robotics)
	Long-Term Cost: Higher due to complications and repeat procedures	Long-Term Cost: Lower due to early detection, fewer complications, and outpatient procedures
Market & Growth	The US GI endoscopic device market is projected to grow from \$5.9B (2023) to \$9.2B (2030)	
	Future market growth will be driven by new tech adoption, increased AI integration, and expanding devices market	
Clinical Outcomes	Effective for acute conditions; limited chronic management	Improved outcomes in IBD, GERD, IBS, GI cancers via precision & innovation

FY26 and Beyond



Positioned for growth

Building on Momentum

- FY25 marked a pivotal year as Optiscan transitioned from development to clinical validation.
- FY26 will see this momentum accelerate, with a focus on commercial readiness and global expansion across veterinary and clinical markets.

Clinical Advancement

- Ongoing breast and gastrointestinal studies in Australia and Germany to generate clinical evidence supporting regulatory submissions.
- Expansion of Optiscan's clinical network in Australia and US to prepare for upcoming trials and collaborations.

Innovation Pipeline

- Continued AI integration to enhance diagnostic interpretation and workflow automation.
- Expansion of the Telepathology Platform deployment for image review and remote collaboration.
- Advancement of next-generation probe and scanner designs for improved imaging depth and usability.


Commercial Readiness

- Transition of InForm™, InVue® and InSpecta™ into full regulatory validation and pre-commercial stages.
- Scaled production and deployment planning to support clinical and research customers.
- Strengthened commercial infrastructure and partnerships across key global regions.

Strategic Outlook

- Progression toward FDA submissions and US market entry.
- Strengthening of applications in surgery, pathology and veterinary medicine.
- Continued investment in partnerships that extend Optiscan's reach across precision health and digital medicine.

Optiscan is entering FY26 with a solid foundation, a strengthened leadership team, and a clear roadmap toward commercialisation.




A category-defining opportunity

This is the leap from analogue to digital, from delay to immediacy - and Optiscan is making it possible.

- **Revolutionary technology** - the only platform delivering high resolution, real-time, sub-cellular, live microscopic imaging.
- **Multi-market growth** – veterinary, pathology, clinical and robotics markets worth billions.
- **Recurring revenue model** - hardware + consumables + SaaS.
- **Validated by global leaders** - Carl Zeiss, Pentax, Mayo Clinic.
- **Inflection point** - proven technology, defined regulatory pathway, market entry underway.

CT and MRI transformed radiology. Optiscan will do the same for pathology.

Optiscan Imaging - medicine's next great leap!



Imaging in action



Questions



THANK YOU FOR YOUR ATTENDANCE



Optiscan^o